Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy

Br J Haematol. 2008 Apr;141(1):129-31. doi: 10.1111/j.1365-2141.2008.07000.x. Epub 2008 Feb 12.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ado-Trastuzumab Emtansine
  • Antibodies, Monoclonal / pharmacology*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / pharmacology*
  • CD56 Antigen / immunology*
  • Cell Division / drug effects
  • Cell Survival / drug effects
  • Dose-Response Relationship, Drug
  • Humans
  • Lymphoma, Extranodal NK-T-Cell / pathology*
  • Maytansine / analogs & derivatives
  • Trastuzumab
  • Tumor Cells, Cultured

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • CD56 Antigen
  • Maytansine
  • Trastuzumab
  • Ado-Trastuzumab Emtansine